

No. 14389/507/2018

Dt. 17/09/2018

CORRIGENDUM

DRUGS AND MEDICAL CONSUMABLES (GROUP-I) -2018-19 ON RATE CONTRACT BASIS FOR THE FINANCIAL YEAR 2018-19.

[Bid Ref. No.: OSMCL/2018-19/DRUGS-DHS-GEN/04]

Sl. No	Item Name/ Particulars	Details as mentioned in the tender document	Queries raised by the prospective bidders	Clarifications/ Amendments in response to the queries.
Queries relating to General Terms and Conditions				
1	<p>Section-2 Clause No. 2.2.2</p> <p>Scope & Rate Contract</p> <p>Page no.- 08</p>	<p>Rate Contract: This is a Rate contract Bid, the rate of which will be valid for a period of one year from the date of finalization of rate contract. However, the approx. quantity requirement is mentioned in the Schedule of Requirement – Section IV, which may increase or decrease substantially as per requirement. The bidders are expected to quote their best rates for the items. The technical specifications, approx. quantity and locations for supply are mentioned in Section IV of this bid document. Only OSMCL is authorized to place purchase orders for the supply of item(s) to be procured under this bid during the validity of the rate contract period.</p>	<p>1.The rate contract should be for an agreed period and fixed quantity.</p> <p>2.Purchase order over and above the tender quantity even if placed during rate contract period cannot be committed / accepted by the supplier.</p>	<p>Clarification:</p> <p>1.The rate contract is valid for 1(one) year from the date of approval and during that period the approved supplier(s) is/are bound to supply the items as per the purchase order placed by OSMCL.</p> <p>2.The quantity mentioned at Coloumn No. 6 of Section IV is an indicative quantity which may increase or decrease substantially as per tender clause no. 6.24.2.</p> <p><i>The purchase order quantity will be based on the intimated award of contract / LOI quantity by OSMCL to the approved supplier(s), the LOI/P.O. quantity will be based on available stock position and consumption pattern of the respective item.</i></p>

2	<p>Section-3 Clause No. 3.1(3) EMD</p> <p>Page no.- 10</p> <p>Section-6 Clause No. 6.7.1 EMD</p> <p>Page no.- 70</p>	<p>Earnest Money Deposit (In shape of DD/BG/BC)</p> <p>The item-wise EMD requirement is mentioned in Section IV (Schedule of Requirement)</p> <p>Note: The bidder may quote for any or all the item(s) by submitting the required EMD for that item.</p> <p>The amount of the EMD(s) to be submitted per item is mentioned at Section III and Non-submission of EMD as mentioned in Section III shall be one of the primary reasons for rejection of the offer in the first round. In case of EMD in shape of BG the validity of BG Shall be valid up to 26.08.2019 i.e. 1(one) year from the date of floating of the tender.</p>	<p>The maximum capping of EMD amount may be fixed, so that bidders can quote maximum number of items in the tender, which will ultimately create a Healthy Competition among the bidders.</p>	<p>Amended. The bidder has to deposit the required EMD amount as mentioned in Section IV (Schedule of Requirement) for each item quoted by him and it should be reflected in Format-T3.</p> <p>However, maximum capping of EMD amount is now fixed to Rupees 1(one) crore. The bidders can participate for all / multiple items by depositing Rs. 1(one) crore towards EMD.</p> <p>However, local MSEs of Odisha are exempted from deposit of EMD as per tender Clause No. 6.7.2</p>
3	<p>Section-V Clause No. 5.2.2 Pre-qualification of bidders</p> <p>Page no.- 64</p>	<p>The manufacturer shall have valid GMP certificate as per Revised Schedule M of Drugs & Cosmetics Rule 1945 / COPP (Certificate of Pharmaceutical Products) / WHO GMP certificate issued by the concerned licensing authority.</p> <p>In case of imported item, WHO GMP (of Manufacturer) /COPP shall be submitted.</p>	<p>1.The manufacturers undergoing renewal of GMP/WHO-GMP with a renewal application duly acknowledged by competent authority may be allowed to participate in the bid.</p> <p>2.Valid WHO-GMP certificate of the manufacturer may be made</p>	<p>Clarification In case of items coming under medical devices GMP certificate is relaxed as per GOI CDSCO clarification No. 29/Misc/03/2018-DC(59) particularly Q. No. 62.</p>

		<p>Note: Valid certificate means the certificates should be valid on the date of opening of technical bids.</p>	<p>mandatory to enable good companies with assured quality medicines to participate in the tender.</p> <p>3. In case of items coming under medical devices according to medical device rules 2017 w.e.f. 01.01.2018, there is no requirement of GMP certification. Hence for those items GMP certification may be relaxed for qualification.</p>	
4	<p>Section- V Clause No. 5.2.5</p> <p>Annual Turnover</p> <p>Page No. 65</p>	<p>Bidder (manufacturer/ importer) shall have minimum turnover of (1) Rs. 15 Crs or more in each of the year for last 3(three) financial years in India from SI. No. 01 to SI. No. 304 , (2) Rs. 10 Crs or more in each of the year for last three financial years in India from SI. No. 305 to SI. No. 402, (3) Rs. 2 Crs or more in each of the year for last 3(three) financial years in India from SI. No. 403 to SI. No. 418 & (4) for the item at SI. No. 419 the bidder shall have minimum turnover of Rs.35 Lakhs or more in each of the year for last three financial years in India. Last 3(three) financial years means either during 2014-15, 2015-16 and 2016-17 or 2015-16, 2016-17 and 2017-18.</p>	<p>1. Each year may be amended to average of three financial years as mentioned.</p> <p>2. The turnover criteria should be relaxed for MSME units of Odisha and as well as other MSME units situated all over India.</p> <p>3. In case of importer, the turnover of the original manufacturer/ parent company should be considered.</p> <p>4. In case of parenteral products the turnover criteria should be increased to 30-35 crores in each</p>	<p>Amended.</p> <p>Local MSE units of ODISHA registered with respective DICs, Khadi, Village, Cottage & Handicraft Industries, OSIC and NSIC within the state of Odisha are now allowed to participate in 22 (twenty two) items with minimum turnover of 35 Lakhs in any one financial year during the last 3(three) financial years i.e. either 2014-15, 2015-16 and 2016-17 or 2015-16, 2016-17 and 2017-18.</p> <p>Further, the local MSE units of Odisha shall have quantity reservation of 20% of the tender/procurement quantity if they agree to supply the items matching with L1 approved rate. <i>For the item (D09002) Tab. Co-trimoxazole</i> whose quantity reservation is already fixed as 25% of the tender/procurement quantity remains unchanged. Detail item list is attached at Annexure-I.</p> <p>However, other than the local</p>

			year.	<i>MSEs the turnover criteria remains unchanged for these 22(twenty two) items as per its turnover fixed in the original tender document.</i>
5	<p>Section- V Clause No. 5.2.8</p> <p>Market Experience</p> <p>&</p> <p>Section- V Clause No. 5.2.9</p> <p>Market Standing</p> <p>Page No. 65</p>	<p>Bidder should have experience in supplying quoted item/Same Molecule of Similar Dosages form as per tender specification to the State or Central Government or Government Hospitals / Corporate Hospitals / PSU Hospitals / Municipal Hospitals / Pvt. Hospitals in India / UN agencies / Authorized agency of the State / Central Govt. / PSU/Open Market Supply as a manufacturer or otherwise during last 3(three) years in Format T7.</p> <p>Bidder should have at least 3 (three) years market standing for the quoted item(s) as per tender specification (In Format T8 / Market standing certificate issued by the licensing authority to establish the 3 years market standing for the quoted item(s) as per tender specification). This certificate is not applicable for non drug items. This would not apply to new drugs; certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect in From-46</p>	<p>1. Three (3) years market standing and market experience for individual items may be relaxed for local MSE units of Odisha who have adequate experience in supplying in other various drugs to Govt. Institutions & open market.</p> <p>2. Three (3) years market standing and market experience for start up units may be relaxed.</p> <p>3. In case of importer, the market experience of the original manufacturer/ parent company should be considered.</p>	No Change

		for exemption.		
6	<p>Section-VI Clause No. 6.24</p> <p>Award of Contract</p> <p>Page No. 80</p>	<p>Criteria :- The contract will be awarded to the lowest evaluated responsive (L1) bidder for the entire tendered quantity or part thereof as per the discretion of management.</p> <p>However, empanelment of other technically qualified bidders may be asked through negotiation to match with the L1 price for supply of the Bulk/Critical/Essential/Program item (s). Subsequently orders can be place to L1, L2 & L3 bidders at L1 rate in the ratio 50:30:20.</p>	25% of the required quantity may be reserved for eligible local MSME units of Odisha who are willing to match with L1 rate.	Refer Sl.No.4 for clarification.
7	<p>Section-VI Clause No. 6.24</p> <p>Supply Conditions</p> <p>Page No. 83</p>	<p>The successful bidder shall have to supply the item(s) within the stipulate period (70 days as mentioned in Clause 5.1.1), at the warehouses / Supply points as mentioned in Section IV - Schedule of Requirement.</p> <p>In case of vaccines, serum, immunoglobulin, blood products like human coagulation factors VII, VIII, IX, etc., which requires quality clearance of the item(s) from CRI Kasauli/ NIB Noida/ Govt. Statutory Laboratories, the items will be accepted based on the above mentioned lab test report only within 90 days from issue of purchase order.</p>	The supply period for vaccine items may be relaxed further upto 120 days and LD should be levied thereafter.	No Change
8	<p>Section-VI</p>	However, in case of small ordered items	In case of vaccine item, 3/4 th shelf life	Clarification/ Amended

	<p>Clause No. 6.28.6</p> <p>Supply Conditions</p> <p>Page No. 84</p>	<p>(i.e. small ordered quantity in comparison to the batch manufacturing size) may be considered for exemption from the above stipulation (Cl. No. 6.28.5) with an undertaking furnished by the supplier that if the item expires not being utilised then the supplier shall replace the whole expired item with fresh batch(es). However, at the time of supply the item should have minimum 70% of the remaining shelf life from the date of manufacture.</p>	<p>may be accepted at the time of supply.</p>	<p>However, in case of small ordered items (i.e. small ordered quantity in comparison to the batch manufacturing size), imported items and in case of vaccines, serums, immunoglobulin's, blood products like human coagulation factors VII, VIII, IX, etc. may be considered for exemption from the above stipulation (Cl. No. 6.28.5) with an undertaking furnished by the supplier that if the item expires not being utilised then the supplier shall replace the whole expired stock of that item with fresh batch(es). <i>However, at the time of supply the item should have minimum 70% of the remaining shelf life from the date of manufacture.</i></p>
9	<p>Section-VI</p> <p>Clause No. 6.28.9</p> <p>Supply Conditions</p> <p>Page No. 85</p>	<p>The items quoted are to be supplied in standard packing with wordings "Govt. of Odisha Supply – NOT FOR SALE" (in Odia and English) to legibly appear in primary, secondary and tertiary packing of all products.</p>	<p>The OSMC logo & wordings "Govt. of Odisha Supply – NOT FOR SALE" (in Odia and English) may be relaxed in case of vaccines.</p>	<p>No Change</p>
10	<p>Section-VI</p> <p>Clause No. 6.28.11</p> <p>Supply Conditions</p> <p>Page No. 85</p>	<p>No goods shall be received after expiry of the penal period (50 days after the normal delivery period of 70 days) i.e. maximum up to 120 [as per Cl. no. 6.28.2 (a)] days from the issue of the purchase order and the purchase order shall stand automatically cancelled without prejudice to penal action as applicable.</p>		<p>Amended:</p> <p>No goods shall be received after expiry of the penal period <i>i.e. 50 days after the normal delivery period of 70 days as per Cl. no. 6.28.2 (a), hence the maximum deliver/supply period is up-to 120 days.</i></p> <p>However, in case of items coming under Cl. no. 6.28.2 (b) i.e. in case of vaccines, serums, immunoglobulin's, blood products like human coagulation factors VII, VIII, IX, etc. which requires quality clearance of the item(s) from CRI Kasauli / NIB Noida / Govt. Statutory Laboratories, the items will be accepted based on the above mentioned lab test report</p>

				with normal delivery period of 90 days from the date issue of purchase order. Hence, accordingly the maximum delivery period shall be up-to 140 days from the date of issue of the purchase order including 50 days of penal period and the purchase order shall stand automatically cancelled without prejudice to penal action as applicable.
11	<p>Section-VI Clause No. 6.30</p> <p>Quality testing</p> <p>Page No. 86</p>	<p>Quality testing and Handling charges: 1.5 % of the purchase order value shall be collected from the approved supplier as the quality testing charges. But the supply of each drug/consumable must be in minimum batches. If more than 1.5% of purchase order value is spent towards quality testing due to more number of batches, the extra cost will be collected from the supplier. The balance amount if any remaining due to less batch and bulk supply out of 1.5% will not be returned to the supplier.</p>	<p>1. Testing charge may be exempted in case of imported items, vaccines, serum, immunoglobulin, blood products like human coagulation factors VII, VIII, IX, etc., which requires quality clearance of the item(s) from CRI Kasauli/ NIB Noida/ Govt. Statutory Laboratories.</p> <p>2. Testing charges @ 1.5% of the PO value may be reduced.</p>	No Change
12	<p>Section-VI Clause No. 6.41</p> <p>Page No. 93</p>	Fall Clause	Fall clause may not be applicable as prices may vary from state to state and should only be applicable within the state of Odisha.	No Change
13	<p>Format T7</p> <p>Performance Statement</p> <p>Page No. 104</p>	<p>The documentary proof will be copies of the purchase orders (during last 3 years) indicating P.O. No. and date.</p> <p>The documentary proof will be certificate from the</p>	<p>1. Order copies of private parties may be accepted.</p> <p>2. Copy of invoices/bills in place of order copies may be accepted.</p>	<p>Clarification:</p> <p>Tender clause no. 5.2.8 and Format- T7 may be referred for clarification.</p> <p>Invoice/bill copies (in proper format) will also be considered as proof of supply as alternate to purchase order copies.</p>

		consignee/end user indicating P.O. No. and date.		
14	Format-T7 (Performance Statement during the last two Years) Page No.76	Cl. No. 6.17.10		Amended Clause no. 6.17.10 is now revised i.e. (Format-T7) Performance Statement during the last 3(three) years based on pre-qualification criteria i.e. tender Cl. No.5.2.8.
15	Section VI Page No. 84	6.28.3:- In case the supplied item(s) not delivered within the stipulated delivery period, the Tender Inviting Authority shall deduct Liquidated Damage (LD) charges as per the bid conditions specified in clause 6.39.5		Amended Clause no. 6.28.3 is now revised i.e. In case the supplied item(s) not delivered within the stipulated delivery period, the Tender Inviting Authority shall deduct Liquidated Damage (LD) charges as per the bid conditions specified in clause 6.38.5 .

Technical Queries

16	Section – IV , Item Sl No. 5, D23011- Inj. Human Anti-D Immunoglobuline Page No. 13	D23011- Inj. Human Anti-D Immunoglobuline 300mcg/ 2ml 20 Amps/ Box	1 ml vial for this item may also be accepted.	Amended (D23011) Inj. Human Anti-D Immunoglobuline 300mcg in 2ml/1ml Amp/Vial 20 Amps/Vials/ Box
17	Section – IV , Item Sl No. 12, D33191- Inj. Ranibizumab Page No. 13	D33191- Inj. Ranibizumab 10 mg/ml/Vial	The packing of the item may be amended to PFS instead of vial.	Amended D33191- Inj. Ranibizumab 10 mg/ml per Vial/PFS 20 Vials/PFS/ Box
18	Section – IV ,	D07005- Tab. Sodium Valproate (Aluminium foil	The technical specification of the	No change

	Item SI No. 64, D07005-Tab. Sodium Valproate (Aluminium foil/ Blister pack) Page No. 19	/ Blister pack) 200 mg/Tab (Controlled Release)	item i.e. “controlled release” may be amended to “Film Coated” .	
19	Section – IV , Item SI No. 136, D09150-Tab. Cefuroxime Axetil (Aluminium foil/ Blister pack) Page No. 24	D09150-Tab. Cefuroxime Axetil (Aluminium foil/ Blister pack) 500mg/ Tab Approx. Quantity: 14,91,500 tabs EMD (in Rs.): Rs. 10,45,000 /-	The quantity or the EMD to be deposited is mismatching.	Amended The EMD amount of D09150- Tab. Cefuroxime Axetil (Aluminium foil/ Blister pack) 500mg is now revised to Rs. 1,57,700 /- instead of Rs. 10,45,000 /- for approx. quantity of 14,91,500 tabs.
20	Section – IV , Item SI No. 154, D16032-Factor VIII (with diluents in plastic or glass container) Page No. 26	D16032 Factor VIII (with diluents in plastic or glass container) 250 IU / vial Each unit Packet shall contain the followings: i) 1 Vial Immunate 250 IU ii) 1 Vial Sterilized required diluent in plastic or glass container iii) 1 Transfer / Filter Set iv) 1 Disposable Syringe : 5 ml v) 1 Disposable Needle vi) 1 Winged Infusion Set / Twin Set All blood products should be “Test Negative for HBsAg, HIV I & II, HCV Antibodies” which will be printed on each unit packet	The term Immunate may be deleted from the specification.	Amended D16032 Factor VIII (with diluents in plastic or glass container) 250 IU / vial. Each unit Packet shall contain the followings: i) 1 Vial 250 IU ii) 1 Vial Sterilized required diluents in plastic or glass container iii) 1 Transfer / Filter Set iv) 1 Disposable Syringe : 5 ml v) 1 Disposable Needle vi) 1 Winged Infusion Set / Twin Set All blood products should be “Test Negative for HBsAg, HIV I & II, HCV Antibodies” which will be printed on each unit packet

21	<p>Section – IV , Item SI No. 155 D16033 Factor VIII (with diluents in plastic or glass container)</p> <p>Page No. 27</p>	<p>D16033 Factor VIII (with diluents in plastic or glass container) 500 IU / vial Each unit Packet shall contain the followings: i) 1 Vial Immunate 500 IU ii) 1 Vial Sterilized required diluent in plastic or glass container iii) 1 Transfer / Filter Set iv) 1 Disposable Syringe : 5 ml v) 1 Disposable Needle vi) 1 Winged Infusion Set / Twin Set All blood products should be “Test Negative for HBsAg, HIV I & II, HCV Antibodies” which will be printed on each unit packet</p>	<p>The term Immunate may be deleted from the specification.</p>	<p>Amended D16033 Factor VIII (with diluents in plastic or glass container) 500 IU / vial. Each unit Packet shall contain the followings: i) 1 Vial 500 IU ii) 1 Vial Sterilized required diluents in plastic or glass container iii) 1 Transfer / Filter Set iv) 1 Disposable Syringe : 5 ml v) 1 Disposable Needle vi) 1 Winged Infusion Set / Twin Set All blood products should be “Test Negative for HBsAg, HIV I & II, HCV Antibodies” which will be printed on each unit packet</p>
22	<p>Section – IV , Item SI No. 156, D16034 Factor IX (with diluents in plastic or glass container)</p> <p>Page No. 27</p>	<p>D16034 Factor IX (with diluents in plastic or glass container) 600 IU / vial Each unit Packet shall contain the followings: i) 1 Vial Immunate 600 IU ii) 1 Vial Sterilized required diluent in plastic or glass container iii) 1 Transfer Needle iv) 1 Filter Needle v) 1 Aeration Needle v) 1 Disposable Syringe : 5 ml vi) 1 Winged Infusion Set / Triple Set All blood products should be “Test Negative for HBsAg, HIV I & II, HCV Antibodies” which will be printed on each unit packet</p>	<p>1. The term Immunate may be deleted from the specification. 2. Either the pack size may be amended to 500 IU or L1 calculation may be done as per unit dose.</p>	<p>Amended D16034 Factor IX (with diluents in plastic or glass container) 600 IU / vial. Each unit Packet shall contain the followings: i) 1 Vial 600 IU ii) 1 Vial Sterilized required diluents in plastic or glass container iii) 1 Transfer Needle iv) 1 Filter Needle v) 1 Aeration Needle v) 1 Disposable Syringe : 5 ml vi) 1 Winged Infusion Set / Triple Set All blood products should be “Test Negative for HBsAg, HIV I & II, HCV Antibodies” which will be printed on each unit packet</p>
23	<p>Section</p>	<p>D16022- Tab.</p>	<p>Strength of 250</p>	<p>No change</p>

	<p>- IV , Item SI No. 157,</p> <p>D16022- Tab. Deferasiro x (Aluminiu m foil/ Blister pack)</p> <p>Page No. 28</p>	Deferasirox (Aluminium foil/ Blister pack) 100 mg/Tab	mg/Tab may also included	
24	<p>Section - IV , Item SI No. 158,</p> <p>D16023- Tab. Deferasiro x (Aluminiu m foil/ Blister pack)</p> <p>Page No. 28</p>	D16023- Tab. Deferasirox (Aluminium foil/ Blister pack) 400 mg/Tab	Strength of 500 mg/Tab may also included	No change
25	<p>Section - IV , Item SI No. 170, D16020- Tab. Iron (Sugar Coated)(Aluminiu m foil/ Blister pack)</p> <p>Page No. 29</p>	D16020- Tab. Iron (Sugar Coated) (Aluminium foil/Blister pack) Equivalent to 100 mg of Elemental Iron	The specification may be amended to -Tab. Ferrous Sulphate I.P.- 200 mg (Equivalent to 60 mg Elemental Iron)	Amended D16020- Tab. Ferrous Sulphate (Sugar Coated) (Aluminium foil/Blister pack) 200 mg (200 mg of dried Ferrous Sulphate is approximately equivalent to 60 mg of Elemental Ferrous iron)
26	<p>Section - IV , Item SI No. 208,</p> <p>D21021- Susp. Sucralfate(Palatable,</p>	D21021- Susp. Sucralfate (Palatable, with measuring cap and plastic container/ Glass Bottle as per I.P.) 1gm/10ml 100ml/Bottle	The strength of the item may be amended to 1 gm/ 5ml.	No Change

	with measuring cap and plastic container/ Glass Bottle as per I.P) Page No. 32	20 Bottles/Box		
27	Section – IV , Item SI No. 212, D21048- Tab. Rabepazole + Domperidone (Aluminium foil/ Blister pack) D21048- Tab. Rabepazole + Domperidone (Aluminium foil/ Blister pack) Page No. 33	D21048- Tab. Rabepazole + Domperidone (Aluminium foil/ Blister pack) Rabepazole 20 mg + Domperidone 30 mg 10 Tabs/Strip 10 Strips/Box	The item may be accepted in “ Capsule ” form along with tablet form.	Amended D21048- Tab./ Cap. Rabepazole + Domperidone (Aluminium foil/ Blister pack) Rabepazole 20 mg + Domperidone 30 mg 10 Tabs /Cap. Per Strip 10 Strips/Box
28	Section – IV , Item SI No. 213, D22003- Tab. Metformin HCl (coated)(Aluminium foil/Blister pack) D22003- Tab. Metformin HCl (coated)(Aluminium foil/Blister pack) Page No. 33	D22003- Tab. Metformin HCl (coated)(Aluminium foil/ Blister pack) 500 mg/Tab	The item may also be accepted in “ Uncoated ” form.	Amended D22003- Tab. Metformin HCl (Aluminium foil/ Blister pack) 500 mg/Tab 10 Tabs Per Strip 10 Strips/Box
29	Section – IV , Item SI No. 280, Page No. 37	D27113- Tab. Varenicline (Aluminium foil/Blister pack) 1 mg/Tab 10 Tabs/Strip 10 Strips/Box	Packing size may be amended to 28 tabs/strip	Clarification The pack size mentioned in column no. 5 Section IV is Preferable Pack Size.
30	Section – IV ,	D27116- Tab. Varenicline (Aluminium	Packing size may be amended to 25	Clarification

	Item SI No. 284, Page No. 38	foil/Blister pack) 0.5 mg/Tab 10 Tabs/Strip 10 Strips/Box	tabs/strip Starter pack- 0.5 mg (1X11) + 1 mg (1X14)= 25 tabs/strip	The pack size mentioned in column no. 5 Section IV is Preferable Pack Size.
31	Section – IV , Item SI No. 294-298, X Ray Photo Film of various sizes Page No. 38	X Ray Photo Film of various sizes Conforming to IS No.15584	1. Standards conforming to European CE or USFDA for these items may be accepted. 2. Submission of Test report at the time of supply for these items may be exempted.	Amended X Ray Photo Film of various sizes Conforming to IS No.15584. However, in case of importer standards conforming to USFDA/CE may also be accepted. Clarification Submission of Internal Test report/Certificate of Analysis/ In-house test report of each batch supplied is a mandatory requirement for acceptance of items at the time of supply.
32	Section – IV , Item SI No. 348, D19009-Soln. Chlorohexidine Gluconate (Plastic Container as per IP) Page No. 43	Chlorohexidine Gluconate + Cetrimide + Isopropyl Alcohol as per IP 500 ml/Bottle 20 bottles/box	The strength of each item may be confirmed.	No change
33	Section – IV , Item SI No. 403, S02110- Bivalent Rapid Diagnostic Test Kit Page No. 50	S02110- Bivalent Rapid Diagnostic Test Kit 10 test/kit/box	Pack size of 25 test/kit/ box may be accepted.	No change Clarification: To claim the RDT Performance Criteria, the bidder must submit relevant documents regarding RDT performance criteria from WHO list of Pre-qualified Quality Control Laboratories.
34	Section – IV , Item SI No. 404, S02111-	S02111- NS1 Elisa Kit For Dengue Test 48/96 test kits / box	The approx. quantity mentioned may be clarified i.e. test or kit and the price to	Amended S02111- NS1 Elisa Kit For Dengue Test

	<p>NS1 Elisa Kit For Dengue Test Page No. 50 and 54 (Technical Specification)</p>	<p>Approx. quantity: 500 EMD (In Rs.): 1000</p>	<p>be quoted in the BOQ as per test or Kit.</p> <p>The Shelf-life of the item at Point No (.E) in technical specification may be changed to 1(one) year instead of 6(six) months.</p>	<p>48/96 test kits / box</p> <p>Approx. Quantity at Column No. 6 is now revised to 48,000 tests. Hence, accordingly the EMD amount is now revised to Rs. 36,500/-.</p> <p>The Shelf-life of (S02111) NS1 Elisa Kit for Dengue Test is now changed to 1(one) year or more in the technical specification Point No. E at page no. 54 of tender document.</p> <p>The price to be quoted in the BOQ/ price bid should be per test.</p>
35	<p>Section – IV , Item SI No. 405,</p> <p>S02113- Whole Blood Finger Prick Test Kit Page No. 50 & Technical Specification Point no. 6 (f) Page No. 59</p>	<p>S02113- Whole Blood Finger Prick Test Kit 30 Test Kits/Box</p> <p>The pack size of HIV rapid test kits should be 30 tests per Kit.</p>		<p>Amended</p> <p>S02113- Whole Blood Finger Prick Test Kit</p> <p>10 Test Kits/Box</p> <p>The pack size of HIV rapid test kits should be 10 tests per Kit.</p>
36	<p>Section – IV , Item SI No. 406,</p>	<p>S02135- Point of Care Test Kit (Rapid Whole Blood Syphilis Test Kit) 30 Test Kits/Box</p>		<p>Amended</p> <p>S02135- Point of Care Test Kit (Rapid Whole Blood Syphilis Test Kit)</p>

	S02135- Point of Care Test Kit (Rapid Whole Blood Syphilis Test Kit) Page No. 50			The pack size of Point of Care Test Kit (Rapid Whole Blood Syphilis Test Kit) should be 10 tests per Kit.
37	Section – IV , Item SI No. 409, D31014- Bleaching Powder Page No. 50	D31014- Bleaching Powder Not Less than 30% w/v available Chlorine 25 kg/Package	Delivery of small quantities to all 39 warehouses is very difficult. So purchase order may be given for one truck load of the item to deliver at any desired destination.	No Change

NB :- The **amended date & time** are as follows:

- The **last date and time** for **online bid submission** is now changed in **NIT** at **Page No.3** and **Section III (Important Dates)** at **Cl. No. 3.2** at **Page No.10**, the revised date and time is :- **Dt.05.10.2018 up-to 6.00 PM.**

General Clarification:-

- The bidders have to quote the prices as per the format mentioned in **Price Bid/ BOQ** in the e—tender portal. The prices (Rates) are to be quoted per tab/ caps/ bottle/ amp./ vial/ PFS/ tube/ Kit/ cylinder/ jar/film/piece/lit./ kg./gm/test etc.(as the case may be) and not in unit pack, the quoted price includes packing, forwarding / transportation & Door Delivery and excludes GST.
- The amendments mentioned above are to be treated as amendments in the technical specification(s) and term(s) and condition(s) of the above tender reference. All other technical specifications and terms conditions remain unchanged.
- Since any text in the price BOQ can't be changed in the e-tender portal, the amendments mentioned in the specifications above are to be treated as amendments in the price bid/ BOQ also.

Sd/

Managing Director

OSMC Ltd., Odisha

Annexure - I

List of items for local MSE units of Odisha to participate in the tender with minimum turnover of Rs. 35 Lakhs or more in any one financial year during last three F.Y & quantity reservation (in %) for the respective items if they match with L1 approved rate

Sl No.	Tender Item Sl No.	Drug Code	Name of the Item	Specification	Quantity Reserve in % of the Tender Quantity / Procured Quantity
1	92	D09077	Tab. Azithromycin (Aluminium Foil/Blister pack)	500 mg/Tab	20%
2	80	D09017	Tab. Norfloxacin (Aluminium Foil/Blister Pack)	400 mg/Tab	20%
3	82	D09020	Tab. Ciprofloxacin HCl (Aluminium Foil/Blister Pack)	500 mg/Tab	20%
4	141	D13008	Tab. Ornidazole (Coated) (Aluminium foil/Blister pack)	500 mg/Tab	20%
5	57	D05021	Tab. Levocetirizine Dihydrochloride(Aluminium foill/ Blister pack)	5 mg/Tab	20%
6	289	D28017	Tab. Doxofylline (Aluminium foill/ Blister pack)	400mg/Tab.	20%
7	38	D04043	Tab. Paracetamol Kid (Scored Disp. Tab.) (Aluminium foill/ Blister pack)	250 mg/ Tab	20%
8	142	D13009	Tab. Metronidazole (Coated)(Aluminium foil/Blister pack)	200 mg/Tab	20%
9	31	D04005	Tab. Ibuprofen (Coated) (Aluminium foill/ Blister pack)	200 mg/Tab	20%
10	238	D27052	Tab. Procyclidine(Aluminium foill/ Blister pack)	5 mg / Tab	20%
11	84	D09033	Tab. Ofloxacin (Aluminium Foil/Blister Pack)	200 mg/Tab	20%
12	93	D09084	Tab. Ofloxacin (Aluminium foil/Blister pack)	400 mg/Tab	20%
13	321	D08004	Tab. Albendazole (Chewable) (Aluminium foill/ Blister pack)	400 MG/TAB	20%
14	320	D08003	Susp. Albendazole(Palatable, with measuring cap(5 ml)and plastic container/ Glass Bottel as per I.P)	200 mg/5ml	20%
15	55	D05011	Syp. Cetrizine Dihydrochloride (Palatable, with measuring cap and plastic container/ Glass Bottle as per I.P)	5 mg/ 5 ml	20%
16	31	D04005	Tab. Ibuprofen (Coated) (Aluminium foill/ Blister pack)	200 mg/Tab	20%
17	204	D21035	Susp./Gel Antacid (Palatable, with measuring cap and plastic container/ Glass Bottel as per I.P)	Magaldrate 400mg + Simethicone 20mg) / 5ml (Mint Flavour)	20%
18	418	D16027	Solution Disodium Hydrogen Citrate(Palatable, with measuring cap and plastic container/ Glass Bottel as per I.P)	1.38 gm to 1.5gm / 5 ml	20%
19	37	D04032	Susp. Ibuprofen (Palatable, with measuring cap and plastic container/ Glass Bottle as per I.P)	100mg / 5ml	20%
20	112	D09138	Susp. Ofloxacin (Palatable, with measuring cap and plastic container/ Glass Bottle as per I.P)	50mg / 5ml	20%

21	391	D09143	Tab. Diethylcarbamazine Citrate (Aluminium Foil / Blister Pack)	100 mg / Tab as per IP 1996 / latest IP. The Shelf life of Tab. DEC should be minimum three years to maximum five years.	20%
22	419	D09002	Tab. Cotrimoxazole (Aluminium foil/ Blister pack)	TMP 80mg + SMZ 400mg / Tab	25%